From: Younger age as a prognostic indicator in breast cancer: A cohort study
Variable | Less than 40 (n = 276) | More than 40 (N = 2869) | P Value |
---|---|---|---|
Age in yrs (SD) # | Â | Â | < 0.001* |
   Mean | 35.81 (3.92) | 60.08 (12.22) |  |
   Median (range) | 37 (20-40) | 59 (41-96) |  |
Tumour size (mm) # | Â | Â | 0.477 |
   Mean | 21.49 | 22.74 |  |
   Median (range) | 20 (1-120) | 20 (1-160) |  |
Tumour grade | Â | Â | 0.044* |
   Grade 0 | 69 (27%) | 697 (26.47%) |  |
   Grade 1 | 23 (9%) | 262 (9.9%) |  |
   Grade 2 | 70 (27.3%) | 912 (34.5%) |  |
   Grade 3 | 94 (36.7%) | 774 (29.3%) |  |
Histology Type | Â | Â | < 0.001* |
   Ductal | 178 (74.2%) | 1768 (72.8%) |  |
   Lobular | 18 (7.5%) | 368 (15.2%) |  |
   Others | 44 (18.3%) | 291(12%) |  |
Tumour stage | Â | Â | 0.046* |
   0 | 17 (7.4%) | 210 (9.2%) |  |
   I | 66 (28.6%) | 538(23.6%) |  |
   II | 93 (40.3%) | 850 (37.3%) |  |
   III | 46 (19.9%) | 477 (20.9%) |  |
   IV | 9 (3.9%) | 202 (8.9%) |  |
ER status | Â | Â | < 0.001* |
   Positive | 123 (58.3%) | 1629 (74.5%) |  |
   Negative | 88 (41.7%) | 559 (25.5%) |  |
PR status | Â | Â | 0.319 |
   Positive | 102 (70.3%) | 1142 (72.5%) |  |
   Negative | 43 (29.7%) | 433 (27.5%) |  |
Her-2 status | Â | Â | 0.002* |
   Positive | 34 (30.6%) | 213 (18.6%) |  |
   Negative | 77 (69.4%) | 935 (81.4%) |  |
Surgical treatment | Â | Â | < 0.001* |
   Mastectomy | 192 (75.9%) | 1647 (61.9%) |  |
   BCS | 61 (24.1%) | 1012 (38.1%) |  |
Adjuvant hormonal therapy | Â | Â | 0.005* |
   Yes | 184 (86.4%) | 2924 (92.4%) |  |
   No | 29 (13.6%) | 159(7.6%) |  |
Adjuvant chemotherapy | Â | Â | 0.021* |
   Yes | 109 (46.2%) | 866 (38.4%) |  |
   No | 127 (53.8%) | 1389 (61.6%) |  |
Adjuvant radiotherapy | Â | Â | 0.778 |
   Yes | 135 (59.2%) | 1234 (58%) |  |
   No | 93 (40.8%) | 892 (42%) |  |